Skip to main content

Table 1 Clinical and laboratory characteristics of patients that received intravenous anakinra

From: Intravenous administration of anakinra in children with macrophage activation syndrome

Patient

Age

Sex

Diagnosis

Anakinra dose (mg/kg/d) Initial Max

Duration (Days)

Triglycerides (mg/dl) baseline

Ferritin (ng/dl) Pre-Post

AST (U/L) Pre-Post

Fibrinogen (mg/dl) Pre-Post

Platelets (1000/UL) Pre post

1

1

M

SJIA

4

7.2

3

109

4667

2132

53

52

504

253

568

505

2

3

F

SJIA

7.4

7.4

11

160

130,000

3486

164

45

168

202

46

70

3

4

M

SJIA

7.8

15.4

5

102

8663

1097

766

160

81

170

84

173

4

6

M

SJIA

20

20

12

Not done

10,437

137

168

24

196

126

211

265

5

8

F

SJIA

8

8

3

83

5160

1954

74

472

426

392

343

591

6

13

F

SJIA

3.3

7.5

10

197

21,442

1442

935

42

83

152

113

267

7

13

F

SJIA

11

11

8

249

55,000

3933

325

107

118

91

120

311

8

16

M

SJIA

9.4

9.4

5

207

2016

294

16

13

637

509

471

429

9

16

M

SJIA

6

6

2

176

17,033

3850

125

120

221

221

180

243

10**

20

F

SJIA

1.7

6.8

5

152

84,000

10

1812

314

170

319

23

81

11

16

F

Lupus

2.5

8

47

268

12,098

412

432

6

323

214

139

150

12

16

M

Lupus

6.6

6.6

10

165

5195

557

361

40

362

607

134

287

13

20

M

Lupus

10

10

85

782

120,000

1421

2521

23

190

158

239

188

14**

13

M

Vasculitis

7.1

14.2

54

203

3186

12,398

46

128

321

779

22

42

15

3

F

sHLH

4

20

16

333

110,000

1240

66

28

335

155

298

290

16

9

M

sHLH

3

11

13

209

15,750

7855

41

42

295

405

709

174

17**

10

F

sHLH

4

8

2

2617

1216

15,577

270

394

674

489

19

99

18**

12

F

sHLH

2.2

4.2

9

336

92,000

67,000

265

26

375

595

12

101

19**

19

F

sHLH

8

8

20

272

13,756

8004

166

134

376

205

60

56

  1. Ravelli criteria include Ferritin> 684 ng/dl plus any 2/3 of TG > 156 mg/dl, PLT < 181 (1000/UL), AST > 48 U/L, Fibrinogen< 360 mg/dl. Values meeting these criteria shown in italics and bold. All patients except patient #1 and #5 met Ravelli criteria 2016, who had elevation in ferritin and elevated AST only
  2. Patient with ** (Patient #10, #14, #17, 18# and #19) are deceased
  3. AST Aspartate aminotransferase, sJIA Systemic Juvenile Idiopathic Arthritis, sHLH secondary hemophagocytic lymphohistiocytosis